Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ruxolitinib-Danazol Evaluated in Myelofibrosis Patients

Leuk Res; ePub 2017 Jun 13; Gowin, Kosiorek, et al

The combination of ruxolitinib and danazol produced hematologic stabilization in patients with myelofibrosis in a small phase 2 study involving 14 individuals.

Investigators looked at the combination’s efficacy and tolerability in high-risk myelofibrosis patients treated at 2 institutions. Among the results:

  • Using International Working Group-Myeloproliferative Neoplasms Research and Treatment criteria, responses were stable disease in 9 patients; clinical improvement in 3 (all spleen responses); partial response in 1; and progressive disease in 1.
  • Anemia and thrombocytopenia were stabilized.
  • 4 of 5 JAK inhibitor naïve patients had stable or increasing hemoglobin.
  • 5 of 9 patients on prior JAK inhibitor had stable or increasing hemoglobin levels; 8 experienced stable or increasing platelet levels.
  • Grade 3 or greater hematologic toxicity occurred in 10 patients.
  • 2 patients experienced non-hematologic toxicity.


Gowin K, Kosiorek H, Dueck A, et al. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. [Published online ahead of print June 13, 2017]. Leuk Res. doi:10.1016/j.leukres.2017.06.005.